Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
pharmaand GmbH
With
Foundation Medicine
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Be 18 years old at the time the informed consent form is signed
Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate
Be surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL (1.73 nM)
Experienced disease progression after having received at least 1 but no more than 2 prior next-generation androgen receptor-targeted therapies, and 1 prior taxane-based chemotherapy, for castration-resistant disease
Have a deleterious mutation in BRCA1/2 or ATM, or molecular evidence of other homologous recombination deficiency
You may not be if
Active second malignancy, with the exception of curatively treated non-melanoma skin cancer, carcinoma in situ, or superficial bladder cancer
Prior treatment with any PARP inhibitor, mitoxantrone, cyclophosphamide or any platinum-based chemotherapy
Symptomatic and/or untreated central nervous system metastases
Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of rucaparib
Clareo Health | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
